Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Depreciation & Amortization (CF) (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Depreciation & Amortization (CF) data on record, last reported at $53201.0 in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) changed 0.0% year-over-year to $53201.0; the TTM value through Dec 2025 reached $211460.0, down 2.7%, while the annual FY2025 figure was $212839.0, 3.08% down from the prior year.
  • Depreciation & Amortization (CF) reached $53201.0 in Q4 2025 per INM's latest filing, roughly flat from $53202.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $55231.0 in Q4 2023 and bottomed at $28532.0 in Q3 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $51486.0, with a median of $53202.5 recorded in 2024.
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 71.91% in 2022, then fell 4.97% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $49797.0 in 2021, then fell by 1.5% to $49049.0 in 2022, then increased by 12.6% to $55231.0 in 2023, then decreased by 3.67% to $53203.0 in 2024, then decreased by 0.0% to $53201.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $53201.0 in Q4 2025, $53202.0 in Q3 2025, and $52752.0 in Q2 2025.